Brief: Maat Pharma Provides Business Objectives And Expected Milestones For 2022

Maat Pharma SA

17/01/2022 17:07

Jan 17 (Reuters) - Maat Pharma SA  MAAT.PA :
    * MAAT PHARMA PROVIDES BUSINESS OBJECTIVES AND EXPECTED
MILESTONES
FOR 2022
    * IMPORTANT CLINICAL MILESTONES ARE EXPECTED IN 2022 IN
COMPANY'S
HEMATO-ONCOLOGY AND IMMUNO-ONCOLOGY PROGRAMS
    * CLINICAL RESULTS ARE EXPECTED IN H1 2022 FOR MAAT033,
COMPANY'S
ORAL CAPSULE FORMULATION DESIGNED TO PREVENT COMPLICATIONS OF
ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (ALLO-HSCT)
    * NEW CGMP MANUFACTURING PLANT: CONTRACTING IS EXPECTED TO
TAKE
PLACE IN H1 2022
    * MAAT033: COMPLETE RESULTS ARE EXPECTED IN FIRST HALF OF
2022 AND
A PIVOTAL PHASE 2/3 MAY BE INITIATED AT END OF 2022 TO EVALUATE
MAAT033 AS A PROPHYLACTIC TREATMENT FOR BLOOD CANCER PATIENTS
UNDERGOING ALLO-HSCT
    * MAAT033: IN Q1 2022, COMPANY WILL PROVIDE INTERIM RESULTS
OF
ENGRAFTMENT DATA FOR PHASE 1B CLINICAL TRIAL

Source text for Eikon:  ID:nBw9HKVd9a 
Further company coverage:  MAAT.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))